Clinical-stage cell therapy company Shanghai Grit Biotechnology ... on broadening the indications of Quanqi (125SER) Interleukin-2 (IL-2) products for solid tumours. Quanqi (125SER) is a marketed ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

Conclusions Treg defects in patients with SLE are associated with IL-2 deficiency, and can be corrected with low doses of IL-2. The restoration of endogenous mechanisms of immune tolerance by low-dose ...

MedStar Georgetown University Hospital is the first hospital in the Washington metropolitan area to offer Tumor-Infiltrating ...

Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Background—In the lipopolysaccharide (LPS) stimulated peripheral blood monocyte, the precursor form of interleukin 1β (IL-1β, 31 kD ... significantly reduced the amount of mature IL-1β released by ...

Non-responders had significantly higher concentrations of interleukin (IL) 23 and IL-10 before and during MTX therapy ... Assessment of Psoriasis and Psoriatic Arthritis guidelines advise methotrexate ...

at the Promise of Interleukin-2 Therapy Conference, taking place at the Centre International de Conférences Sorbonne Université in Paris, France, from September 4-7, 2024. The Company will ...

Immunotherapy represents a groundbreaking approach to combating various diseases by harnessing and enhancing the body’s ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T ...

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...